Medicare GLP-1 Bridge: $50/month Wegovy, Zepbound, Foundayo starts July 1

Starting July 1, 2026, Medicare will offer a new “Medicare GLP-1 Bridge” option that can make certain GLP-1 weight-loss medicines more affordable for some people with Medicare drug coverage (Part D).

If you qualify, you’ll pay a flat $50 monthly copay for a one-month supply—through December 31, 2027. But eligibility is specific, and the program uses a prior authorization process plus a lifestyle-treatment requirement.

Quick basics: what the Bridge covers

The Medicare GLP-1 Bridge is a short-term demonstration run by CMS (Centers for Medicare & Medicaid Services). It operates outside the usual Medicare Part D drug-payment flow. That affects how the copay is handled and how it shows up (or doesn’t) on Part D statements.

Under the program, Medicare covers these GLP-1 drugs for weight management (for eligible patients):

Foundayo (tablet)
Wegovy (injection or tablet)
Zepbound (KwikPen only; the program doesn’t cover single-dose vials or pens)

Coverage is available nationwide to eligible people with Medicare drug coverage (Part D), including certain Medicare Advantage plans with drug coverage and other Part D plan types.

The key eligibility questions

On Medicare.gov, eligibility is described as a checklist you answer with your clinician when starting GLP-1 therapy. The main categories include:

1) Age

You must be 18 or older when you start GLP-1 therapy.

2) BMI (body mass index) and certain health conditions

To qualify, you must meet a BMI threshold and, for some BMI ranges, also have at least one qualifying condition when you start GLP-1 therapy. Medicare.gov lists these options:

BMI 35 or more
BMI 30–34.99 plus at least one qualifying condition, such as diastolic heart failure (HFpEF), uncontrolled high blood pressure (hypertension), chronic kidney disease stage 3a or higher, prediabetes, prior heart attack or stroke, or peripheral artery disease with symptoms
BMI 27–29.99 plus at least one qualifying condition, such as prediabetes, prior heart attack or stroke, or peripheral artery disease with symptoms

3) Whether you already get a GLP-1 through your Part D plan

You’re not eligible if you already get GLP-1 drugs covered through your Medicare Part D plan.

4) Certain diagnoses that change eligibility

Medicare.gov states that you are not eligible for the Bridge if you have:

Type 2 diabetes
Moderate-to-severe sleep apnea
Fatty liver disease

Medicare.gov notes that your Part D plan might cover GLP-1 medicines for those conditions.

Who is not eligible (and what happens instead)

If someone already gets a GLP-1 through their Medicare Part D plan—or has type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease—the Bridge isn’t available right now for that person.

In many cases, the next step is to talk with the prescriber and review coverage options under the person’s existing Part D plan, because Medicare.gov indicates their Part D coverage may still apply for GLP-1 treatment tied to certain diagnoses.

Cost & coverage mechanics: what the $50 copay really means

Under the Bridge, Medicare.gov describes the $50 copayment as:

Paid to the pharmacy for a one-month supply (either 28 or 30 days, depending on the drug)
Handled through a separate Medicare program that runs outside regular Part D coverage and payment flow

Because it’s outside the Part D benefit flow, CMS and Medicare.gov say the $50 copay:

Does not apply to the Part D deductible
Does not count toward your TrOOP (true out-of-pocket costs)
Is not lowered by low-income subsidy support (often called Extra Help)

Medicare.gov also notes that the copayment doesn’t count toward the yearly deductible or out-of-pocket limit and doesn’t appear on standard Part D statements like the Explanation of Benefits (EOB) or the Medicare Summary Notice (MSN).

Prior authorization and the lifestyle requirement

To get the Bridge-covered prescription filled at the $50 copay, your clinician must take key steps:

Send a prescription for a covered GLP-1 to the pharmacy
When requested, complete a prior authorization
Certify the medication is being used as part of a lifestyle program focused on diet and exercise

Medicare.gov also states that the prior authorization is valid (including for refills and dose changes) through December 31, 2027, unless you switch GLP-1s.

Practical next steps for readers

Check the official eligibility checklist on Medicare.gov (“Weight loss drugs” / Medicare GLP-1 Bridge).
Gather your basics before your appointment: age, recent weight/height (for BMI), and any qualifying conditions your clinician would document.
Tell your prescriber you’re asking about the Bridge—and confirm that the paperwork will include the required prior authorization and the lifestyle-program certification.
Ask the pharmacy what to expect for processing and whether they need any Medicare information to submit/track the prior authorization.
Plan for timing: coverage depends on getting the Bridge prior authorization approved for a covered GLP-1 drug.

What the evidence says (and what remains uncertain)

GLP-1 medicines have been studied in large clinical trials. For example, the SELECT trial (semaglutide) was a randomized, placebo-controlled study in people with overweight or obesity without diabetes who had preexisting cardiovascular disease; results supported a reduction in a composite cardiovascular outcome versus placebo. Like any trial, its results apply to the study population and dosing used—and do not automatically translate to every patient or every coverage program.

Professional guidance from the American Diabetes Association emphasizes that weight management pharmacotherapy should be paired with lifestyle approaches (nutrition, physical activity, and behavioral support) and individualized to a patient’s overall health context. This matters for the Bridge, which explicitly requires a lifestyle-focused program certification.

Still, the Bridge is a time-limited demonstration, so real-world effects—such as how uptake, adherence, and outcomes change for eligible Medicare beneficiaries—are part of what CMS is monitoring.

Bottom line

The Medicare GLP-1 Bridge can lower the upfront cost barrier for some eligible Medicare Part D beneficiaries starting July 1, 2026—at a predictable $50/month copay through December 31, 2027.

But eligibility hinges on specific age, BMI/health-condition criteria and whether someone already receives GLP-1 coverage through their Part D plan for certain diagnoses. If you’re exploring coverage, start with the Medicare.gov checklist and make sure your prescriber submits the required prior authorization and lifestyle-program certification.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.